TY - JOUR
T1 - Insulin-like growth factor-I ameliorates delayed kidney graft function and the acute nephrotoxic effects of cyclosporine
AU - Maestri, Marcello
AU - Dafoe, Donald C.
AU - Adams, Greeg A.
AU - Gaspari, Annalisa
AU - Luzzana, Francesco
AU - Innocente, Francesco
AU - Rademacher, Johannes
AU - Dionigi, Paolo
AU - Barbieri, Annalisa
AU - Zonta, Franco
AU - Zonta, Aris
AU - Rabkin, Ralph
PY - 1997/7/27
Y1 - 1997/7/27
N2 - Background. Delayed graft function (DGF) is a relatively common complication after cadaveric renal transplantation. The adverse effect of DGF on long-term graft survival has lead to intensive efforts to reduce ischemic graft injury. In this study we examined the effects of a new protective treatment based on insulin growth factor (IGF)-I. We evaluated the impact of the treatment on renal recovery and on the nephrotoxicity that is a common side effect of mainstream immunosuppressants. Because therapy with IGF-I or the analog des(1-3)IGF-I is effective in treating experimental ischemic renal failure, these peptides may be useful as perspective clinical treatments. Methods. We have addressed three areas relating to the potential use of IGF- I and its analog des(1-3)IGF-I. First, because of the immunogenic properties of IGF-I, we assessed the effect of des(1-3)IGF-I on the rejection of skin allografts in Lewis rats. Next we determined whether treatment with des(1- 3)IGF-I influences the early function of transplanted kidneys in a model of DGF induced by a combination of warm and cold ischemia. Finally we tested whether IGF-I protects against acute cyclosporine nephrotoxicity. Results. Des(1-3)IGF-I did not accelerate the rejection of the skin grafts (P=0.57). The administration of this peptide in a model of syngenic renal transplant improved the early function of the graft. Postoperative values of creatinine and blood urea nitrogen were significantly better (P
AB - Background. Delayed graft function (DGF) is a relatively common complication after cadaveric renal transplantation. The adverse effect of DGF on long-term graft survival has lead to intensive efforts to reduce ischemic graft injury. In this study we examined the effects of a new protective treatment based on insulin growth factor (IGF)-I. We evaluated the impact of the treatment on renal recovery and on the nephrotoxicity that is a common side effect of mainstream immunosuppressants. Because therapy with IGF-I or the analog des(1-3)IGF-I is effective in treating experimental ischemic renal failure, these peptides may be useful as perspective clinical treatments. Methods. We have addressed three areas relating to the potential use of IGF- I and its analog des(1-3)IGF-I. First, because of the immunogenic properties of IGF-I, we assessed the effect of des(1-3)IGF-I on the rejection of skin allografts in Lewis rats. Next we determined whether treatment with des(1- 3)IGF-I influences the early function of transplanted kidneys in a model of DGF induced by a combination of warm and cold ischemia. Finally we tested whether IGF-I protects against acute cyclosporine nephrotoxicity. Results. Des(1-3)IGF-I did not accelerate the rejection of the skin grafts (P=0.57). The administration of this peptide in a model of syngenic renal transplant improved the early function of the graft. Postoperative values of creatinine and blood urea nitrogen were significantly better (P
UR - http://www.scopus.com/inward/record.url?scp=0030860990&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030860990&partnerID=8YFLogxK
U2 - 10.1097/00007890-199707270-00001
DO - 10.1097/00007890-199707270-00001
M3 - Article
C2 - 9256171
AN - SCOPUS:0030860990
VL - 64
SP - 185
EP - 190
JO - Transplantation
JF - Transplantation
SN - 0041-1337
IS - 2
ER -